Body Pharm MOTS-C 32mg

The MOTS-c 32mg peptide pen from Body Pharm is a pre-mixed, refrigerated subcutaneous injection device supplied for laboratory research use only. Each batch is traceable to ISO/IEC 17025-aligned HPLC purity testing and shipped under MHRA-compliant unlicensed-research conditions. The 32mg fill more than doubles the 15mg format common among UK suppliers in 2024, cutting per-mg handling overhead for extended preclinical protocols, researchers can administer multiple doses from a single sealed cartridge without reconstitution or repeated vial entries.

MOTS-c itself is a 16-amino-acid mitochondrial-derived peptide, first characterised as an exercise-induced regulator of AMPK signalling and metabolic homeostasis by Reynolds et al., Nature Communications, 2021. This article covers the mechanism, the pen's storage and stability profile at 2–8°C, the batch documentation chain, and the UK regulatory framing under which this product is sold for research.

Key Takeaways

• MOTS-c is a 16-amino-acid mitochondrial-derived peptide that activates AMPK signalling and metabolic homeostasis pathways in preclinical models.
• The 32mg pre-filled pen removes the reconstitution step, reduces handling variability, and delivers fixed-concentration doses from a sealed cartridge.
• Each batch includes HPLC purity verification (≥98%) and mass spectrometry identity confirmation under ISO/IEC 17025-aligned methods.
• The evidence base is strong for metabolic regulation and exercise mimicry in rodent models; human clinical data remain limited as of 2026.
• The product is supplied for laboratory research use only and is not a licensed medicine in the UK.

What Is MOTS-c? The Mitochondrial Peptide Explained

MOTS-c is a 16-amino-acid mitochondrial-derived peptide (MDRP) encoded within the 12S rRNA region of mitochondrial DNA. Lee et al. first characterised it in Cell Metabolism in 2015, and it is now one of the most-studied members of the MDRP class. Unlike nuclear-encoded peptides translated in the cytosol from chromosomal genes, MOTS-c originates in the mitochondrial genome itself, placing it within a small group of retrograde signalling molecules that communicate mitochondrial status to the rest of the cell.

As of 2026, its primary research areas cluster around four mechanisms:

• Metabolic regulation via AMPK (Adenosine Monophosphate-activated Protein Kinase) pathway activation in skeletal muscle and liver tissue. Lee et al. 2015 identified this as the primary route for glucose handling improvement.
• Insulin sensitivity, where preclinical rodent models show improved glucose handling under high-fat-diet challenge. AMPK activation enhances glucose uptake and oxidative capacity.
• Mitochondrial biogenesis and stress-responsive nuclear translocation. Work from 2022–2023 clarified how mitochondrial stress drives MOTS-c into the nucleus.
• Exercise mimicry, formalised by Reynolds et al. in Nature Communications (2021). The peptide activates the same metabolic pathways as physical activity, positioning it as an exercise-induced regulator of age-dependent physical decline in mice.

Human clinical data remain limited. The evidence base through 2026 is predominantly cell and animal model work. Findings from Lee 2015 and Reynolds 2021 should be read as foundational rather than current. Researchers planning administration parameters should consult the MOTS-c dosing protocol or the broader peptide guides and dosing protocols hub.

MOTS-c Research Areas: What Studies Show in 2026

The MOTS-c evidence base in 2026 spans four research domains. Metabolic and exercise-mimicry data are the most robust, resting on peer-reviewed mechanistic work from 2015 onwards. Longevity findings remain confined to preclinical models because no human lifespan trials have been completed. Researchers selecting MOTS-c for a protocol should weight Lee et al. 2015 and Reynolds et al. 2021 as anchor citations, supported by a 2022–2023 wave of mechanistic refinements rather than new human trials.

Insulin sensitivity and glucose metabolism

Lee et al. 2015 (Cell Metabolism) established MOTS-c as an AMPK-activating peptide that improved glucose handling in high-fat-diet rodent models. This remains the strongest mechanistic finding in the literature; the AMPK activation pathway has been independently confirmed across multiple cell and tissue models. Subsequent 2022–2023 preclinical work has reinforced the AMPK–skeletal muscle–liver axis without altering the original conclusions. Evidence strength: strong preclinical, no published human trials as of 2026.

Mitochondrial biogenesis and energy homeostasis

MOTS-c exhibits stress-responsive nuclear translocation. Mitochondrial stress drives the peptide into the nucleus to regulate adaptive gene expression. The mechanism was refined by 2022–2023 follow-on papers building on the original Lee 2015 framework, with researchers identifying the specific stress signals that trigger nuclear import. This domain is mechanistically well-characterised in cell models but has not generated human biomarker data of note through mid-2026.

Exercise mimicry and skeletal muscle function

Reynolds et al. 2021 (Nature Communications) positioned MOTS-c as an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline in mice. The peptide showed improved running capacity and metabolic flexibility in aged animals by activating AMPK and mitochondrial biogenesis pathways similar to physical training. Citation analysis through 2024–2025 shows the paper has been extended rather than contradicted by later reviews.

Longevity and ageing biology

Longevity claims rest entirely on rodent and cell models as of 2026, with no phase I/II human lifespan trials reported in major journals. Procurement decisions framed around ageing endpoints should treat the evidence as early-stage; the mechanistic findings have not yet been validated in human populations.

For administration parameters in a specific protocol, see the MOTS-c dosing protocol or the wider peptide guides and dosing protocols hub.

Why a 32mg Injection Pen vs. a Lyophilised Vial?

A 32mg pre-filled MOTS-c pen removes the reconstitution step entirely. It delivers pre-measured subcutaneous doses from a sealed multi-dose injection pen cartridge stored at 2–8°C. A lyophilised vial requires bacteriostatic water reconstitution, manual aliquoting, and frozen storage at −20°C between uses. Each of those steps can affect dose accuracy.

Reconstitution as a preparation variable

Lyophilised MOTS-c vials introduce three handling steps before the first dose: diluent selection, reconstitution volume calculation, and aliquoting. Each is a potential source of concentration drift, particularly across long protocols where the same researcher may not prepare every aliquot. A pre-filled pen ships at a fixed concentration validated against the 32mg total payload. The dose per click is determined at manufacture rather than at the bench, reducing inter-aliquot variability.

Some researchers worry that pre-filled pens may degrade faster than lyophilised powder. The Body Pharm MOTS-c 32 is formulated with stabilisers to maintain potency at 2–8°C: sealed and unused it holds a 24-month shelf life, and once pierced and in use it should be finished within 12 months. Batch-specific stability data are available on request.

What "multi-dose" means in practice

In a research setting, the 32mg payload is dialled out across multiple subcutaneous administrations using the pen's internal dose selector. Each actuation draws from the same sealed cartridge. This matters for extended protocols because a single pen can cover a multi-week schedule without the researcher reopening primary packaging, re-reconstituting, or thawing a frozen aliquot. The septum is pierced only by the disposable pen needle, which reduces the contamination vectors associated with repeated vial entries.

Body Pharm QC note (2026)

Each Body Pharm MOTS-c pen is dose-validated before sealing, with concentration verified against the labelled payload prior to cartridge assembly. Pens are released for dispatch at 2–8°C, protected from light, and must not be frozen. Compared with a standard lyophilised vial workflow, the pen format removes pipetting error at the point of use and shortens the chain of custody between QC release and the subcutaneous injection site because the dose is pre-measured and sealed.

For administration parameters specific to this format, see the MOTS-c dosing protocol, or the broader peptide guides and dosing protocols hub.

Body Pharm MOTS-c 32: Product Specification

The Body Pharm UK MOTS-c 32 is a 16-amino-acid mitochondrial-derived peptide supplied as a 32mg pre-filled multi-dose subcutaneous injection pen, released for research use only. Each pen ships with batch-specific documentation covering HPLC purity verification and mass spectrometry identity confirmation, aligned with ICH Q6A/Q6B specifications and ISO/IEC 17025-accredited analytical methods.

Specification block

For administration parameters, see the MOTS-c dosing protocol. Cross-format handling notes sit within the wider peptide guides and dosing protocols hub.

Quality, Sourcing & Batch Traceability

Every MOTS-c 32 pen leaves our facility with a batch-specific Certificate of Analysis tying the unit in your hand to the analytical record on file. Three things travel with the product: the batch number printed on the pen and outer carton, the HPLC purity verification result (≥98%) with test date, and the mass spectrometry identity confirmation referencing the expected 16-amino-acid sequence.

"EU laboratory standard" in this context refers to analytical methods aligned with ICH Q6A/Q6B impurity frameworks and run under ISO/IEC 17025-accredited conditions, rather than a peptide-specific directive that does not exist. A batch number cross-referenced to a dated Certificate of Analysis is verifiable because the analytical data can be independently requested. Vague claims without traceable documentation carry no research value.

What you receive and how to verify it

Pens ship in sealed pharmaceutical packaging with tamper-evident closure. Broken seals invalidate the chain of custody between our QC release and your fridge, which matters for research integrity. Researchers can request the underlying HPLC chromatogram and MS spectrum for any batch number by quoting it to our technical team before procurement sign-off.

For administration parameters after QC acceptance, see the MOTS-c dosing protocol, with format-specific handling within the broader peptide guides and dosing protocols hub.

Subcutaneous Injection: Research Administration Notes

Subcutaneous injection is the administration route used in the original peer-reviewed MOTS-c work, and the route the 32mg pen format is engineered for. The pre-filled solution is optimised for fine-gauge needle delivery, ships at a fixed concentration, and removes the reconstitution step required with lyophilised vials, reducing handling variability between research sessions.

We do not publish dosing figures on this product page. Full volume-per-click conversions, frequency considerations, and storage-after-first-use parameters sit in the MOTS-c dosing protocol, with adjacent format and handling notes in our peptide guides and dosing protocols hub.

Institutional approvals

MOTS-c is supplied for laboratory research use only. It is not a licensed medicine in the UK. Researchers are responsible for ensuring any administration in a study is covered by their institutional protocol, ethics approval, and local biosafety documentation before the pen is brought into use.

UK Ordering, Shipping & Returns

Body Pharm UK ships every MOTS-c 32mg peptide pen order free of charge via Royal Mail tracked delivery. Most UK addresses receive the parcel within 1–3 working days from dispatch. Orders leave our facility in plain, unbranded outer packaging with no peptide or supplier markings on the exterior, which suits both institutional and home-lab delivery addresses.

Returns and research-use-only status

Unused, unopened pens may be returned within 14 days of delivery for a refund or replacement. Once a pen has been opened or its tamper-evident seal broken, it cannot be returned, as cold-chain integrity and sterility can no longer be verified post-dispatch. All products are supplied for research use only and are not for human or veterinary consumption.

Procurement teams planning a study schedule can cross-reference handling parameters in the MOTS-c dosing protocol and wider format notes in our peptide guides and dosing protocols hub before placing a bulk order.

MOTS-c in the Context of Longevity Research

MOTS-c occupies a distinct mechanistic niche within longevity peptide research. It is a mitochondrial-derived peptide encoded within the 12S rRNA mitochondrial DNA region, acting upstream of nuclear stress-response pathways rather than through cofactor supply. That separates it from NAD+ precursors such as NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). NAD+ precursors feed sirtuin-dependent signalling by raising intracellular NAD+ pools, providing the substrate for NAD+-consuming enzymes. The two are complementary rather than interchangeable: MOTS-c activates AMPK signalling whilst NAD+ precursors support sirtuin activity, which is worth bearing in mind for procurement teams building stacks.

Reynolds et al. 2021 (Nature Communications) remains the anchor citation for MOTS-c's role as an exercise-induced regulator of age-dependent physical decline and metabolic homeostasis in mice. Follow-on work between 2022 and 2025 has extended AMPK activation and stress-responsive nuclear translocation findings without overturning the original conclusions. Human longevity trial data are not yet available as of 2026.

Combination protocols pairing MOTS-c with NAD+ precursors or metabolic peptides are an active preclinical area. Researchers scoping stack designs can review the broader longevity category range and cross-reference the NAD+ dosing guide when planning parallel-arm studies.

Frequently Asked Questions

What is the MOTS-c 32mg peptide pen?

The MOTS-c 32mg peptide pen is a pre-filled subcutaneous injection device containing 32mg of synthetic MOTS-c, a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA mitochondrial DNA region. Each Body Pharm pen is batch-tested by HPLC for ≥98% purity and identity-confirmed by mass spectrometry under ISO/IEC 17025-aligned methods. The format is intended for laboratory research use only.

Is MOTS-c available in the UK?

Yes. MOTS-c is legally available in the UK as an unlicensed substance for use in licensed laboratory research facilities. It is not a controlled drug under the Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. UK suppliers, including Body Pharm UK, may not market it for human or veterinary use.

How does MOTS-c differ from other mitochondrial-derived peptides?

MOTS-c signals primarily through AMPK activation and stress-responsive nuclear translocation, regulating metabolic homeostasis and exercise-mimetic effects in preclinical models. This distinguishes it mechanistically from humanin and the SHLP family, which are encoded in the 16S rRNA region and act predominantly through cytoprotective and apoptosis-modulating pathways, targeting different downstream signalling cascades. For administration parameters in research models, see the MOTS-c dosing protocol.

How is the Body Pharm MOTS-c 32 pen stored?

Store the pen refrigerated at 2–8°C, upright, protected from light. Do not freeze. Unopened shelf life is 24 months; once first pierced (in use), use it within 12 months. If refrigeration isn't available it stays stable at room temperature (up to 30 °C) for up to 30 days, but beyond that window prolonged room-temperature exposure should be avoided because it accelerates peptide degradation.

Is MOTS-c for human consumption?

No. MOTS-c is an unlicensed substance supplied strictly for in vitro and preclinical laboratory research use only, with no therapeutic claims made. Human longevity or efficacy trial data are not available as of 2026.

How quickly will my UK order arrive?

UK orders placed before the daily cut-off are dispatched same-day via Royal Mail tracked delivery, typically arriving within 1–3 working days. Temperature-controlled packaging maintains 2–8°C in transit.

Ready to order?

To procure the Body Pharm MOTS-c 32mg peptide pen, add the pen to your basket and request the batch-specific Certificate of Analysis at checkout, or contact our technical team to pre-verify a batch HPLC chromatogram and MS spectrum before sign-off. The peptide guides and dosing protocols hub has further research support material.